title: Hormonal changes induced by short-term administration of gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development.
abstract: Several regimens have been developed to administer gonadotropin-releasing hormone agonists in association with human menopausal gonadotropins (hMG) during follicular growth stimulation for in vitro fertilization. The aim of this study was to characterize hormonal changes induced by short-term administration of agonist, and to evaluate a putative impact of the flare-up effect on follicular recruitment and subsequent IVF. Eighteen highly selected patients were randomely divided in two groups. Nine patients received a short-term administration of Buserelin (Hoechst, AG, Franfurt/Main, FRG) (day 1). They were compared with 9 patients who were exposed to a long-term protocol (day 21), and 13 control patients. Agonist-induced luteinizing hormone (LH) and follicle-stimulating hormone (FSH) increase, in early follicular phase, stimulated follicular growth, shortened follicular phase, and induced a transient rise in progesterone. This was followed by a phase of reduced LH secretion associated with a significant modification of LH immunoreactivity. The short-term regimen did not improve the follicular recruitment, and appeared to reduce the oocytes fertilization rate and embryo quality when compared with prolonged administration of peptide.
authors.affiliation: Department of Obstetrics and Gynecology, University of Louvain, Brussels, Belgium.
authors.forename: E
authors.initials: E
authors.lastname: Loumaye
authors.forename: L
authors.initials: L
authors.lastname: Vankrieken
authors.forename: S
authors.initials: S
authors.lastname: Depreester
authors.forename: I
authors.initials: I
authors.lastname: Psalti
authors.forename: S
authors.initials: S
authors.lastname: de Cooman
authors.forename: K
authors.initials: K
authors.lastname: Thomas
mesh_terms: D002064:Buserelin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004624:Embryo Transfer; D004622:Embryo, Mammalian / Q000502:physiology*; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D005640:Follicle Stimulating Hormone / Q000097:blood; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D007247:Infertility, Female / Q000097:blood* / Q000503:physiopathology / Q000628:therapy; D007986:Luteinizing Hormone / Q000097:blood; D008596:Menotropins / Q000008:administration & dosage; D006080:Ovarian Follicle / Q000502:physiology; D011374:Progesterone / Q000097:blood; D011897:Random Allocation
chemical_list: D006023:Glycoproteins; D011374:Progesterone; D004958:Estradiol; D008596:Menotropins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin